Application of DPP4 as a tumor marker for NK / T cell lymphoma
By discovering the high expression of DPP4 in NK/T cell lymphoma and hindering the chemotaxis mechanism of NK cell, new tumor markers and therapeutic targets are provided, and the limitations of NK/T cell lymphoma treatment in the prior art have been solved. and heterogeneity issues, achieving accurate treatment and screening of patients.
Patent Information
- Application Number
- CN202311349072.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-10-17
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2043-10-17
AI Technical Summary
The existing technology is difficult to effectively explain the pathogenic mechanism and tumor progression mechanism of NK/T cell lymphoma, and the treatment plans for advanced, recurrent and refractory patients are localized and challenging, with high heterogeneity and lack of new treatments. Targets and precision treatment strategies.
DPP4 was used as a tumor marker for NK/T cell lymphoma, and the high expression of DPP4 in tumor cells was detected by single-cell transcriptome sequencing and immunofluorescence co-staining. It was found that it hindered the chemotaxis of normal NK cells, and DPP4 was developed. Inhibitors serve as therapeutic targets.
As an important tumor marker and therapeutic target, DPP4 can be used for precise typing and precise treatment, improve patient survival, and promote the screening and treatment of NK/T cell lymphoma.
Smart Images

Figure CN117568477B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biological detection, and particularly relates to the application of DPP4 as a tumor marker for NK / T cell lymphoma. Technical Background
[0002] NK / T cell lymphoma is a type of non-Hodgkin lymphoma with a low incidence but rapid malignant progression. Its onset is strongly correlated with Epstein-Barr virus infection, and the lesions of most patients manifest as invasion of the nasal cavity or nasopharynx. Clinically, the higher expression of P-glycoprotein in tumor cells of NK / T cell lymphoma leads to its resistance to traditional lymphoma chemotherapy regimens containing anthracyclines (such as the CHOP regimen), so a multi-drug combination and synchronous / sequential radiotherapy regimen that includes non-anthracycline drugs (L-aspartase or pegaspargase) is required. These discoveries and improvements have greatly improved the clinical treatment efficacy of NK / T cell lymphoma, and the 5-year overall survival rate of early patients can reach 70% or even higher. Despite this, patients with advanced, relapsed, and refractory NK / T cell lymphoma account for about 30% of the total, and their prognosis is still poor, and treatment options are more limited and challenging. In recent years, with the continuous improvement of cancer treatment technology, new targeted and immunotherapy regimens (such as immune checkpoint inhibitors and histone deacetylase inhibitors) have also been tried in the treatment of NK / T cell lymphoma patients and have achieved certain results. However, the efficacy of new treatment regimens is not stable, and the degree of treatment response varies greatly among patients. Therefore, this suggests that NK / T cell lymphoma patients have a high degree of heterogeneity, and there is an urgent need to find new therapeutic targets and design new precision treatment strategies to target this heterogeneity.
[0003] The heterogeneity of NK / T cell lymphoma mainly includes the following aspects: First, in terms of the source type of tumor cells, NK / T cell lymphoma is divided into different categories of NK cell origin and T cell origin. Patients with T cell origin only account for a small part, and different cell morphologies from small to large are formed during the transformation from normal lymphocytes to NK / T cell lymphoma tumor cells; at the level of genetic background, our previous studies have found that there are changes in the sequence of genetic loci located in genes such as HLA-II and IL18RAP in the human population. These changes in genetic loci cause human susceptibility to NK / T cell lymphoma, and thus the population can be divided into more susceptible groups and non-susceptible groups based on genetic background; at the molecular level, different teams at home and abroad have analyzed DNA and RNA sequencing data through high-throughput sequencing, and discovered specific somatic mutations and transcriptional disorders in NK / T cell lymphoma, and then molecularly genotyped patients based on this information and designed corresponding treatment strategies. The above studies revealed the high heterogeneity in NK / T cell lymphoma patients from different levels. However, these findings are still insufficient to effectively explain the pathogenic mechanism and tumor progression mechanism of NK / T cell lymphoma.
[0004] In addition to tumor cells, there are also a large number of infiltrating immune cells in tumor tissues, which together with tumor cells constitute a tumor microenvironment structure with heterogeneous characteristics. In recent years, with the popularization of single-cell transcriptome sequencing technology, a large number of studies have explored the heterogeneous immune cells and stromal cell components in the tumor microenvironment of various cancers, and combined with other methods to reveal the relationship between these immune microenvironment components and tumor development and patient treatment response. Previous studies have reported that there are also a large number of immune cell infiltrations in NK / T cell lymphoma tissues, but the specific composition of these immune microenvironment components and their relationship with the development of NK / T cell lymphoma are still unknown. Therefore, it is urgent to find important molecules, key cell populations and cell interaction pairs that are closely related to the development of tumors from the perspective of the tumor microenvironment, so that they can be used as new and effective tumor markers and therapeutic targets for NK / T cell lymphoma, and ultimately improve the survival rate of patients. Summary of the invention
[0005] In view of the defects of the prior art, the object of the present invention is to provide a new tumor marker for NK / T cell lymphoma and its application, so as to solve the problems raised in the above background technology.
[0006] The present invention provides the use of DPP4 (dipeptidyl peptidase 4) as a tumor marker for NK / T cell lymphoma.
[0007] On the other hand, the present invention also provides the use of a DPP4 detection reagent in preparing a kit for screening NK / T cell lymphoma.
[0008] Preferably, the kit comprises the nucleotide sequences shown as SEQ ID NO:1 and SEQ ID NO:2.
[0009] On the other hand, the present invention also provides use of a DPP4 inhibitor in the preparation of a medicament for treating NK / T cell lymphoma.
[0010] Preferably, the DPP4 inhibitor includes one or more of linagliptin, alogliptin, anagliptin, begoloizumab, gemagliptin, omagliptin, saxagliptin, sitagliptin, trelagliptin, and vildagliptin.
[0011] The expression level of DPP4 in each cell type in the peripheral blood and tumor tissue of NK / T cell lymphoma patients was detected by single-cell transcriptome sequencing, and it was found that DPP4 was significantly highly expressed in tumor cells. The expression of DPP4 in NK / T cell lymphoma tumor cells can be detected by immunofluorescence co-staining of paraffin-embedded wax block sections of tumor tissue, and it was found that DPP4 was widely and abundantly expressed in tumor cells. The present invention also found that DPP4 expressed by NK / T cell lymphoma tumor cells can effectively degrade chemokines such as CXCL2, CXCL9 and CXCL10, and the expression level of DPP4 in tumor tissue is negatively correlated with the protein content of CXCL2, CXCL9 and CXCL10 chemokines. Further functional experiments confirmed that DPP4 expressed by tumor cells hindered the chemotaxis of normal NK cells, which can be used for accurate classification and precise treatment of NK / T cell lymphoma patients in clinical practice. In addition, the inhibitory effect of DPP4 on normal NK cell chemotaxis can be inhibited by DPP4 inhibitors. Therefore, DPP4 can be used as an important target for the treatment of NK / T cell lymphoma, and DPP4 inhibitors can be used to treat NK / T cell lymphoma patients. As a tumor marker for NK / T cell lymphoma, DPP4 can be promoted and applied to the screening (primary screening) of NK / T cell lymphoma patients in clinical practice. BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Figure 1 The expression level and expression ratio of DPP4 in various types of cells in the single-cell transcriptome sequencing data of NK / T cell lymphoma are shown.
[0013] Figure 2 The results of immunofluorescence co-staining experiments are shown.
[0014] Figure 3 The results of Western blotting are shown.
[0015] Figure 4The intensity of the CXCL2 / CXCL9 / CXCL10 / CXCL11-DPP4 interaction between tumor cell subsets and myeloid cell subsets obtained by cell communication analysis based on single-cell transcriptome sequencing data of NK / T cell lymphoma is shown.
[0016] Figure 5 It is a schematic diagram of the in vitro chemotaxis experiment between the cell supernatant derived from NK / T cell lymphoma tumor cells and normal NK cells.
[0017] Figure 6 The migration rate of NK cells in different treatment groups obtained by in vitro chemotaxis experiments of cell supernatants derived from NK / T cell lymphoma tumor cells and normal NK cells is shown. A: blank control, chemokine, DPP4 protein, DPP4 inhibitor, chemokine + DPP4 protein, chemokine + DPP4 protein + DPP4 inhibitor; B: cell supernatant (YT cells), cell supernatant (YT cells) + chemokine, cell supernatant (YT cells) + chemokine + DPP4 inhibitor, cell supernatant (NK-92 cells), cell supernatant (NK-92 cells) + chemokine, cell supernatant (NK-92 cells) + chemokine + DPP4 inhibitor.
[0018] Figure 7 The results of multi-color immunofluorescence co-staining experiments are shown. A: DPP4 high expression; B: DPP4 low expression. DETAILED DESCRIPTION
[0019] In order to more clearly understand the above-mentioned objects, features and advantages of the present invention, the present invention is further described in detail below in conjunction with the accompanying drawings and specific examples. It should be understood by those skilled in the art that the examples are only to help understand the present invention and should not be regarded as specific limitations of the present invention; unless otherwise specified, the sequencing and analysis methods used in the following examples are conventional methods.
[0020] Example 1: DPP4 is highly expressed in NK / T cell lymphoma patients
[0021] A total of 10 tumor tissue samples from NK / T cell lymphoma patients from the Sun Yat-sen University Cancer Center were collected for single-cell transcriptome sequencing. In short, the NK / T cell lymphoma tumor tissue samples were first enzymatically digested to obtain a single cell suspension, and then the commercial single-cell transcriptome library kit (10x Genomics) was used to load the living cells and build a library. Finally, the obtained cDNA library was subjected to high-throughput sequencing to obtain a sequence file. The acquired single-cell transcriptome sequencing data was analyzed to obtain all cell types covered in the tumor tissues of NK / T cell lymphoma patients, including normal NK cells, tumor NK cells, T cells, B cells, myeloid cells, and other cells. Figure 1 The expression level and expression ratio of DPP4 in various types of cells in the single-cell transcriptome sequencing data of NK / T cell lymphoma are shown. Among them, DPP4 is mainly expressed in tumor NK cells, but basically not expressed in normal NK cells or other cell types, indicating that the expression of DPP4 is a unique feature of NK / T cell lymphoma tumor cells.
[0022] On the other hand, the paraffin-embedded wax block sections of NK / T cell lymphoma tumor tissue were subjected to immunofluorescence co-staining, and the cell lines of NK / T cell lymphoma were detected by real-time fluorescence quantitative PCR and Western blotting. In the immunofluorescence co-staining experiment, a CD56-specific antibody (Zsbio; Cat#ZM-0057) was used to mark the tumor cells in the tumor tissue wax block sections, and a DPP4-specific antibody (CST; Cat#67138) was used to mark the DPP4 protein in the tumor tissue, and the expression of DPP4 in the tumor cells of NK / T cell lymphoma was determined by detecting the corresponding fluorescent signal. The primer sequences (SEQ ID NO: 1 and SEQ ID NO: 2) used in the real-time fluorescence quantitative PCR experiment of NK / T cell lymphoma cell lines are shown in Table 1 below to detect the expression of DPP4 transcription level.
[0023] Table 1. Real-time fluorescence quantitative PCR primer sequences
[0024]
[0025] The oligonucleotide chain sequences of the above primers were synthesized by Guangzhou Paizhen Biotechnology Co., Ltd.
[0026] Western blotting also used the above-mentioned DPP4-specific antibody to detect cell lysate samples and separated supernatants of NK / T cell lymphoma cell lines to clarify the expression and secretion of DPP4 in tumor cells.
[0027] The above method further confirmed the expression of DPP4 in NK / T cell lymphoma tumor cells, and the presence of cell-secreted DPP4 molecules in the tumor cell supernatant (such as Figure 2 and Figure 3 shown). Figure 2 The figure shows the expression of DPP4 in tumor cells in paraffin-embedded wax block sections of NK / T cell lymphoma tumor tissue detected by immunofluorescence co-staining experiment (CD56 and DPP4 double-positive cells). Figure 3 The figure shows that Western blotting confirmed the expression and secretion of DPP4 protein in the cell lysate and cell supernatant of NK / T cell lymphoma tumor cell lines (YT cells and NK-92 cells), respectively.
[0028] Example 2: Highly expressed DPP4 in NK / T cell lymphoma can hinder the chemotactic recruitment of normal NK cells
[0029] CellPhoneDB software was used to perform cell communication analysis on the single-cell transcriptome sequencing data of the above-mentioned NK / T cell lymphoma patients, and significant cell-cell interactions between tumor cell subpopulations and immune cell subpopulations were obtained. Figure 4 The strength of the interaction between the CXCL2 / CXCL9 / CXCL10 / CXCL11-DPP4 pair between tumor NK cell subsets and myeloid cell subsets is shown. Figure 4 As shown, it was found that all tumor NK cell subsets (NK_C5_ISG15, NK_C6_ITM2A, NK_C7_CCL4, NK_C8_MT1E, NK_C9_CXCL13 and NK_C10_STMN1) can exert the function of DPP4 to degrade chemokines through the above-mentioned interactions.
[0030] Furthermore, by conducting in vitro chemotaxis experiments with cell supernatants derived from NK / T cell lymphoma tumor cells and normal NK cells, we observed whether the cell supernatants that potentially contain DPP4 secreted by tumor cells have an inhibitory effect on the chemotaxis of normal NK cells, and whether this effect can be further inhibited by DPP4 inhibitors. Figure 5It is a schematic diagram of the in vitro chemotaxis experiment of cell supernatants derived from NK / T cell lymphoma tumor cells and normal NK cells. The cell supernatants from NK / T cell lymphoma tumor cell lines pretreated with the small molecule inhibitor of DPP4, Linagliptin (CAS No.: 668270-12-0; Selleck; Cat#S3031) or DSMO control (Sigma-Aldrich; Cat#D4540) were used to treat normal NK cells, thereby confirming that secreted DPP4 exists in the supernatant of NK / T cell lymphoma tumor cells, and can hinder the chemotaxis of normal NK cells through its degradation of chemokines (CXCL2, CXCL9, CXCL10). Finally, the ratio of NK cells that migrate through the small hole into the lower chamber is used to represent its chemotaxis strength. The higher the migration rate, the stronger the chemotaxis ability of normal NK cells in the treatment group. Figure 6 The migration rates of NK cells in different treatment groups obtained from in vitro chemotaxis experiments of cell supernatants derived from NK / T cell lymphoma tumor cells and normal NK cells are shown (A: blank control, chemokine, DPP4 protein, DPP4 inhibitor, chemokine + DPP4 protein, chemokine + DPP4 protein + DPP4 inhibitor; B: cell supernatant (YT cells), cell supernatant (YT cells) + chemokine, cell supernatant (YT cells) + chemokine + DPP4 inhibitor, cell supernatant (NK-92 cells), cell supernatant (NK-92 cells) + chemokine, cell supernatant (NK-92 cells) + chemokine + DPP4 inhibitor). The chemotaxis of normal NK cells caused by chemokines (CXCL2, CXCL9, CXCL10) is inhibited by DPP4, and this inhibitory effect is inhibited by DPP4 inhibitors.
[0031] The DPP4 inhibitor Linagliptin can specifically target DPP4. Here, Linagliptin is used as an example to illustrate the specific embodiments of the present invention. However, based on the basic principles of the present invention, the DPP4 inhibitor of the present invention includes but is not limited to Linagliptin. Other DPP4 inhibitors can also be applied to the present invention and fall within the scope of protection of the present invention, such as Alogliptin (SYR-322; CAS No.: 850649-61-5), Anagliptin (CAS No.: 739366-20-2), Begelomab (SAND-26; CAS No.: 1403744-56-8), Gemigliptin (LC15-0444; CA S number: 911637-19-9), Omarigliptin (MK-3102; CAS number: 1226781-44-7), Saxagliptin (BMS-477118; CAS number: 361442-04-8), Sitagliptin (MK-0431; CAS number: 486460-32-6), Trelagliptin (SYR-472; CAS number: 865759-25-7), Vildagliptin (LAF-237; CAS number: 274901-16-5).
[0032] Furthermore, the paraffin-embedded wax block sections of NK / T cell lymphoma tumor tissues were subjected to multicolor immunofluorescence co-staining to detect the correlation between the protein expression of DPP4 and chemokines (CXCL2, CXCL9, CXCL10) in tumor tissues. In addition to using the above-mentioned CD56 and DPP4 specific antibodies to mark tumor cells and DPP4 protein expression, chemokine-specific antibodies - CXCL2 (Proteintech; Cat#26791-1-AP), CXCL9 (Proteintech; Cat#22355-1-AP) and CXCL10 (Proteintech; Cat#10937-1-AP) were also used in the immunofluorescence co-staining experiment to clarify the expression of these chemokines in NK / T cell lymphoma tissues.
[0033] Figure 7The expression of a small amount of chemokines (CXCL2, CXCL9, CXCL10) in NK / T cell lymphoma patients with high expression of DPP4 (A) is shown, as opposed to the expression of a large amount of chemokines in patients with low expression of DPP4 (B). This result further indicates that tumor cells of NK / T cell lymphoma can degrade chemokines by expressing DPP4, thereby hindering the chemotactic recruitment of normal NK cells into tumor tissues.
[0034] From the above research results, it can be seen that DPP4 expressed by tumor cells hinders the chemotaxis of normal NK cells and can be used for accurate classification and precise treatment of NK / T cell lymphoma patients in clinical practice. The inhibitory effect of DPP4 on the chemotaxis of normal NK cells can be inhibited by DPP4 inhibitors. Therefore, DPP4 can be used as an important target for the treatment of NK / T cell lymphoma, and DPP4 inhibitors can be used to treat NK / T cell lymphoma patients. As a tumor marker for NK / T cell lymphoma, DPP4 can be promoted and applied to the screening (initial screening) of NK / T cell lymphoma patients in clinical practice.
Claims
1. Use of a DPP4 inhibitor in the preparation of a medicament for treating NK / T cell lymphoma, wherein the DPP4 inhibitor is linagliptin.
